Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12779139 | 0.81 | DRD4 (0.32) | DRD4DRD3 | |
| SCHEMBL23425908 | 0.80 | EPHB3 (0.42) | DRD4DRD3DRD2EPHB3 | |
| SCHEMBL25099101 | 0.79 | EPHB3 (0.43) | DRD4DRD3DRD2EPHB3 | |
| SCHEMBL23133667 | 0.79 | KCNH2 (0.37) | DRD4DRD3DRD2 | |
| SCHEMBL25045806 | 0.76 | EPHB3 (0.32) | EPHB3 | |
| SCHEMBL25044276 | 0.75 | — | — | |
| SCHEMBL18309178 | 0.75 | CYP11B2 (0.40) | — | |
| SCHEMBL26779153 | 0.75 | NQO1 (0.41) | DRD4DRD3DRD2 | |
| SCHEMBL26779173 | 0.73 | HRH3 (0.36) | DRD4DRD3DRD2 | |
| SCHEMBL9610941 | 0.70 | DRD3 (0.58) | DRD4DRD3DRD2EPHB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575337-B2 | Oxazolidinone derivative having fused ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098471-A1 | OXAZOLIDINONE DERIVATIVE HAVING FUSED RING | OXER1, ALOX12, CYP1A1 | DRD4 845/4885DRD3 377/4885DRD2 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.